Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

BACKGROUND: Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with placebo. We evaluated the cost-effectiveness of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieg, Maximilian, Hartmann, Michael, Settmacher, Utz, Arefian, Habibollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171756/
https://www.ncbi.nlm.nih.gov/pubmed/32316925
http://dx.doi.org/10.1186/s12876-020-01241-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171756/
https://www.ncbi.nlm.nih.gov/pubmed/32316925
http://dx.doi.org/10.1186/s12876-020-01241-y

Ejemplares similares